Review highlights gaps in reporting quality of nonpharmacological treatments in Chinese medicine

Nonpharmacological treatments in Chinese medicine (NPTCM), including acupuncture, cupping, moxibustion, and Tuina, have gained global recognition for their efficacy in various health conditions.

Atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a | Psychedelic Invest

NEW YORK and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment

June 20, 2024

New program launched to accelerate access to personalized therapies for children with rare conditions

Today, Wednesday 22 November, the government announced its support for the Rare Therapies Launch Pad, a new programme that will develop a pathway for children

December 4, 2023

Long-Term Data in Frontline RCC Raise More Questions Than Answers

At the American Society of Clinical Oncology (ASCO) annual meeting, researchers reported long-term updates from various phase III trials on first-line treatment options for advanced

June 28, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.